u/Intrepid_Web5454

The author argues Sana Biotechnology's immune-evasive insulin-producing islets have survived one year in a human without immunosuppression, validating its anti-rejection technology and positioning it as a potential first-to-market type 1 diabetes cure years ahead of competitors. The mechanism is that Sana's immune evasion avoids the need for immunosuppression, which the author notes caused a patient death in Vertex's VX880 trial. The catalyst is a Phase 1 trial of lab-grown insulin-producing cells starting this year, with the author expecting the cells to produce adequate insulin for several years. The author acknowledges insulin expression was reduced at 52 weeks, which the CEO attributed to donor islet age rather than rejection.